Skandinaviska Enskilda Banken AB publ Buys 41,732 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Skandinaviska Enskilda Banken AB publ lifted its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 36.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 155,684 shares of the biotechnology company’s stock after purchasing an additional 41,732 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Iovance Biotherapeutics were worth $1,115,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in IOVA. AlphaQuest LLC increased its holdings in Iovance Biotherapeutics by 63.6% in the 4th quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 1,794 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Iovance Biotherapeutics in the fourth quarter worth approximately $36,000. Impact Partnership Wealth LLC purchased a new stake in shares of Iovance Biotherapeutics in the fourth quarter worth $83,000. Clear Creek Financial Management LLC bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at $91,000. Finally, KBC Group NV lifted its stake in shares of Iovance Biotherapeutics by 105.7% during the 4th quarter. KBC Group NV now owns 12,303 shares of the biotechnology company’s stock valued at $91,000 after buying an additional 6,321 shares in the last quarter. 77.03% of the stock is owned by hedge funds and other institutional investors.

Iovance Biotherapeutics Price Performance

Shares of IOVA opened at $3.74 on Tuesday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -2.51 and a beta of 0.93. Iovance Biotherapeutics, Inc. has a 1 year low of $3.48 and a 1 year high of $15.90. The business’s 50 day simple moving average is $5.40 and its 200-day simple moving average is $7.96.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, meeting the consensus estimate of ($0.26). Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. The business had revenue of $73.69 million during the quarter, compared to analyst estimates of $72.17 million. On average, sell-side analysts expect that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Truist Financial cut their price target on Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Chardan Capital decreased their target price on Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Piper Sandler lowered their price target on Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating on the stock in a report on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of Iovance Biotherapeutics in a report on Friday, February 28th. Finally, The Goldman Sachs Group lowered their target price on shares of Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Iovance Biotherapeutics has an average rating of “Moderate Buy” and a consensus price target of $20.25.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.